Chemopreventive drug treatment in subjects with genetic predisposition to cancer: Prescriber liability and healthcare disparities

Pharmacogenomics

Volumn 5, Issue 3, 2004, Pages 319-329

  Palmer, Larry I ^a   Martin, Robert C G ^b   Hein, David W ^b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Chemoprevention; Genetic susceptibility; Healthcare disparities; Medical liability; Risk management

Indexed keywords

ANTINEOPLASTIC AGENT; ARYLAMINE ACETYLTRANSFERASE; BRCA1 PROTEIN; BRCA2 PROTEIN; CELECOXIB; CLOMIFENE; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; RALOXIFENE; TAMOXIFEN;

BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CATARACT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE EXACERBATION; ENDOMETRIUM CANCER; ENVIRONMENTAL FACTOR; GASTRITIS; GENETIC PREDISPOSITION; HEALTH CARE SYSTEM; HOT FLUSH; HUMAN; LEGAL ASPECT; MEDICAL DECISION MAKING; MEDICAL ETHICS; MEDICAL LIABILITY; NONHUMAN; PHARMACOGENOMICS; REVIEW; RISK MANAGEMENT; THROMBOSIS; UPPER GASTROINTESTINAL BLEEDING; VAGINA DISCHARGE;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; DELIVERY OF HEALTH CARE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIABILITY, LEGAL; MALE; NEOPLASMS; PENETRANCE;

EID: 16544394563     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/phgs.5.3.319.29832     Document Type: Review

References (62)

1. Jemal A, Thomas A, Murray T et al.: Cancer statistics. CA Cancer J. Clin. 52, 23-47 (2002).
2. Yancik R, Ries LA: Aging and cancer in America. Demographic and epidemiologic perspectives. Hematol. Oncol. Clin. N. Amer. 14, 17-23 (2000).
3. Muss HB: Older age - not a barrier to cancer treatment. N. Engl. J. Med. 345, 1128-1129 (2001).
4. Novelli G, Margiotti K, Reichardt JK: Pharmacogenetics of human androgens and prostatic diseases. Pharmacogenomics 2, 65-72 (2001).
5. Rosen EM, Fan S, Pestell RG, Goldberg ID: BRCA1 gene in breast cancer. J. Cell Physiol. 196, 19-41 (2003).
6. Miki Y, Swensen J, Shattuck-Eidens D et al.: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66-71 (1994).
7. Wooster R, Bignell G, Lancaster J et al.: Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789-792 (1995).
8. Schrag D, Kuntz KM, Garber JE, Weeks JC: Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 283, 617-624 (2000).
9. Easton DF, Ford D, Bishop DT: Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 56, 265-271 (1995).
10. Ford D, Easton DF, Stratton M et al.: Genetic heterogenicity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Corsortium. Am. J. Hum. Genet. 62, 676-689 (1998).
11. Grady WM: Genetic testing for high-risk colon cancer patients. Gastroenterology 124, 1574-1594 (2003).
12. Perera FP: Environment and cancer: who are susceptible? Science 278, 1068-1073 (1997).
13. Lichtenstein P, Holm NV, Verkasalo PK et al.: Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 343, 78-85 (2000).
14. Shields PG, Harris CC: Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J. Clin. Oncol. 18, 2309-2315 (2000).
15. Mucci LA, Wedren S, Tamimi RM, Trichopoulos D, Adami HO: The role of gene-environmental interaction in the aetiology of human cancer: examples from cancers of the large bowel, lung, and breast. J. Int. Med. 24, 477-493 (2001).
16. Patrianakos C, Hoffmann D: Chemical studies on tobacco smoke. LXIV. On the analysis of aromatic amines in cigarette smoke. J. Anal. Toxicol. 3, 150-154 (1979).
17. Layton DW, Bogen KT, Knize MG, Hatch FT, Johnson VM, Felton JS: Cancer risk of heterocyclic amines in cooked foods: an analysis and implications for research. Carcinogenesis 16, 39-52 (1995).
18. El-Bayoumy K: Environmental carcinogens that may be involved in human breast cancer etiology. Chem. Res. Toxicol. 5, 585-590 (1992).
19. Miller EC, Miller JA: Search for the ultimate chemical carcinogens and their reaction with cellular macromolecules. Cancer 47, 2327-2345 (1981).
20. Hein DW, Doll MA, Rustan TD et al.: Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 14, 1633-1638 (1993).
21. Hein DW, Doll MA, Fretland AJ et al.: Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidem. Biomarker Prev. 9, 29-42 (2000).
22. Ambrosone CB, Freudenheim JL, Sinha R et al.: Breast cancer risk, meat consumption and N-acetyltransferase (NAT2) genetic polymorphisms. Int. J. Cancer 75, 825-830 (1998).
23. Huang CS, Chern HD, Shen CY, Hsu SM, Chang KJ: Association between N-acetyltransferase 2 (NAT2) genetic polymorphism and development of breast cancer in post-menopausal Chinese women in Taiwan, an area of great increase in breast cancer incidence. Int. J. Cancer 82, 175-179 (1999).
24. Chang-Claude J, Kropp S, Jager B, Bartsch H, Risch A: Differential effect of NAT2 on the association between active and passive smoke exposure and breast cancer risk. Cancer Epidem. Biomarker Prev. 11, 698-704 (2002).
25. van der Hel OL, Peeters PH, Hein DW et al.: NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women. Pharmacogenetics 13, 399-407 (2003).
26. Minchin RF, Reeves PT, Teitel CH et al.: N- and O-acetylation of aromatic and heterocyclic amine carcinogens by human monomorphic and polymorphic acetyltransferases expressed in COS-1 cells. Biochem. Biophys. Res. Commun. 185, 839-844 (1992).
27. Hein DW, Rustan TD, Ferguson RJ, Doll MA, Gray K: Metabolic activation of aromatic and heterocyclic N-hydroxyarylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases. Arch. Toxicol. 68, 129-133 (1994).
28. Deitz AC, Zheng W, Leff MA et al.: N-aceryltransferase-2 genetic polymorphism, well-done meat intake, and breast cancer risk among postmenopausal women. Cancer Epidem. Biomarker Prev. 9, 905-910 (2000).
29. Le Marchand L, Hankin JH, Wilkens LR et al.: Combined effects of well-done red meat, smoking, and rapid N-acetyltransferase 2 and CYP1A2 phenotypes in increasing colorectal cancer risk. Cancer Epidem. Biomarker Prev. 10, 1259-1266 (2000).
30. Hu JJ, Mohrenweiser HW, Bell DA, Leadon SA, Miller MS: Symposium overview: genetic polymorphisms in DNA repair and cancer risk. Toxicol. Appl. Pharmacol. 185, 64-73 (2002).
31. Sporn MB, Dunlop NM, Newton DL, Smith JM: Prevention of chemical carcinogenesis by vitamin Aand its synthetic analogs (retinoids). Fed. Proc. 35, 1332-1338 (1976).
32. Hong WK: General keynote: the impact of cancer chemoprevention. Gynecol. Oncol 88, S56-S58 (2003).
33. Fisher B, Bryant J, Dignam JJ et al.: Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J. Clin. Oncol. 20, 4141-4149 (2002).
34. Fisher B, Costantino JP, Wickerham DL et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90, 1371-1388 (1998).
35. King MC, Wieand S, Hale K et al.: Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286, 2251-2256 (2001).
36. Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet 2, 104-107 (1896).
37. Jensen EV, Jacobson HI: Basic guides to the mechanism of estrogen action. Recent Prog. Horm. Res. 18, 387-414 (1962).
38. Fisher B, Costantino J, Redmond C et al.: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N. Engl. J. Med. 320, 479-484 (1989).
39. Gail MH, Costantino JP, Bryant J et al.: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J. Natl. Cancer Inst. 91, 1829-1846 (1999).
40. Bernstein L, Deapen D, Cerhan JR, Borgen PI: Tamoxifen therapy for breast cancer and endometrial cancer risk. J. Natl. Cancer Inst. 91, 1654-1662 (1999).
41. Port ER, Montgomery LL, Heerdt AS et al.: Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann. Surg. Oncol. 8, 580-585 (2001).
42. Cummings SR, Eckert S, Krueger KA et al.: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281, 2189-2197 (1999).
43. Steinbach G, Lynch PM, Phillips RK et al.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342, 1946-1952 (2000).
44. Palmer LI: Medical liability for pharmacogenomics. In: Pharmacogenomics: Social, Ethical and Clinical Dimensions. Rothstein MA (Ed.), John Wiley & Sons, Inc., Hoboken, NJ, USA 187-206 (2003).
45. Rachliniski J: A positive psychological theory of judging in hindsight. In: Behavioral Law and Economics. Sunstein C (Ed.), Cambridge University Press, Cambridge, UK 95-115 (2000).
46. Studdert DM, Mello MM, Brennan TA: Medical malpractice. N. Engl. J. Med. 350, 283-292 (2003).
47. Canterbury vs Spence, 464 F. 2d 772 (D. C. Cir 1972).
48. Arato vs Avedon, 23 Cal. Rptr. 131 (Cal. 1993).
49. Moore vs Regents of the University of California, 271 Cal. Rptr. 146 (Cal. 1990).
50. Johnson vs Kodemoor, 545 N. W. 2d 495 (Wis. 1996).
51. Twerski AD, Cohen NB: The second revolution in informed consent: comparing physicians to each other. NW. L. Rev. 94, 1-49 (1999).
52. Langheir JM, Snyderman R: Prospective medicine: the role for genomics in personalized health planning. Pharmacogenomics 5(1), 1-8 (2004).
53. Palmer LI: Disease management and liability in the human genome era. Vill. L. Rev. 47, 1-36 (2002).
54. Committee of Quality of Health Care in America. In: Crossing the Quality Chasm: a New Health System for the 21st Century. Institute of Medicine, National Academy Press, Washington, DC (2001)
55. Royal C, Baffoe-Bonnie A, Kittles R et al.: Recruitment experience in the first phase of the African-American hereditary prostate cancer (AAHPC) study. Ann. Epidem. 10(58), S68-S77 (2000).
56. Burchard EG, Ziv E, Colye N et al.: The importance of race and ethnic background in biomedical research and clinical practice. N. Engl. J. Med. 348, 1170-1175 (2003).
57. Cooper RS, Kaufman JS, Ward R: Race and genomics. N. Engl. J. Med. 348, 1160-1170 (2003).
58. Marchant GE: Genomics and toxic substances: Part II-Genetic susceptibility to environmental agents. Environmental Law Reporter 33, 10641-10667 (2003).
59. Berstein A: Muss es sein? Not necessarily, says torts law. Law & Contemporary Problems 63, 4 (In Press).
60. Grimes vs Kennedy Krieger Institute, Inc. 782 A. 2d 807 (Md. 2001).
61. Komesar NK: Imperfect Alternatives: Choosing Institutions in Law, Economics, and Public Policy. University of Chicago Press, Chicago, IL, USA (1994).
62. Abelson R: Hospitals say they're penalized by Medicare for improving care. New York Times (December 5, 2003).